Skip to main content
Explore URMC

URMC Logo

menu
URMC / News / Tissue Stiffness is a "Mosh Pit” Where Cancer Cells Thrive

Tissue Stiffness is a "Mosh Pit” Where Cancer Cells Thrive

Wednesday, December 05, 2018

 

Imagine being at a packed concert hall with a mosh pit full of dancers creating a wall against outsiders. When targeted drugs try to make their way toward a pancreas tumor, they encounter a similar obstacle in stiff tissue that surrounds and protects the cancer.

A new University of Rochester study demonstrates how imaging technology can be used to accurately measure tissue stiffness — thereby predicting the likelihood that drugs will be able get through to the tumor and guide drug penetration.

“Being able to ‘see’ stiff tissue in the tumor microenvironment is a detection strategy that could help oncologists plan treatments for their patients and monitor progress,” said senior author Marvin Doyley, Ph.D.

photo of Marvin Doyley and the graduate students in his lab
Investigator Marvin Doyley, on far right, with graduate students Rifat Ahmed and April Wang.

In recently published data in the journal Clinical Cancer Research, Doyley’s team showed for the first time in a mouse model a clear correlation between tissue stiffness and high tissue pressure, the characteristic that stops drugs from targeting the tumor. They also showed that a type of imaging called elastography, which is similar to ultrasound technology, can display tissue stiffness on an ultrasound screen.

In fact, their technique is as easy to read as a weather map. The imaging technology uses sound waves to hunt down stiff and high-pressure tissue, and then projects the tumor and stiff tissue in colorful hues, with blues and greens depicting softer tissue, and hotter colors such as red and reddish-brown representing stiff tissue.

Tissue stiffness is an important factor in cervical and breast cancer as well as pancreatic cancer, but Doyley said he was struck by the dismal five-year survival rate of less than 7 percent in pancreas cancer and chose to initially focus on ways to boost outcomes for that disease.

A medical physicist and associate professor of Electrical and Computer Engineering and Biomedical Engineering, Doyley is collaborating with David Linehan, M.D., director of clinical operations at UR Medicine’s Wilmot Cancer Institute, and a surgeon/scientist who also has a special interest in pancreatic cancer. For years Linehan has been investigating the critical role the microenvironment plays in promoting pancreas tumors, and he has designed clinical trials for drugs that stimulate the immune system to attack pancreas tumors.

Their collaboration recognizes that chemotherapy followed by surgery is currently the best treatment, and therefore reducing tissue stiffness is critical for that goal.

Doyley and Linehan are seeking funding to continue the investigation in humans. They would like to confirm that ultrasound technology can be used effectively to guide drug delivery; their team is also working with Wilmot scientist Edward Brown, Ph.D., an associate professor of Biomedical Engineering, who studies the collagen-rich fibers near tumors that contribute to tissue stiffness and cancer metastasis.  

The National Institutes of Health supported Doyley’s study, which was a partnership with the Thayer School of Engineering at Dartmouth College. First author on the paper is UR graduate student April Wang; UR graduate student Rifat Ahmed also played a key role in the research.

# # #

The University of Rochester Medical Center is home to approximately 3,000 individuals who conduct research on everything from cancer and heart disease to Parkinson’s, pandemic influenza, and autism. Spread across many centers, institutes, and labs, our scientists have developed therapies that have improved human health locally, in the region, and across the globe. To learn more, visit urmc.rochester.edu/research.

Media Contact

Leslie Orr

(585) 275-5774

article hit counter